Literature DB >> 15139793

Vancomycin: pharmacokinetics and administration regimens in neonates.

Matthijs de Hoog1, Johan W Mouton, John N van den Anker.   

Abstract

This review describes the use of vancomycin in neonates over the last three decades. Given the relation of late-onset neonatal septicaemia to outcome and the increase in coagulase-negative staphylococcal infection as causative organism, vancomycin remains an important antibacterial in the neonatal intensive care unit. The pharmacokinetic behaviour of vancomycin in neonates can be adequately described by a one- or two-compartment model and is mainly determined by postconceptional age and renal function. In neonates, a patent ductus arteriosus as well as treatment with indomethacin or extracorporeal membrane oxygenation (ECMO) leads to an increase in volume of distribution and a decrease in clearance. Microbiological studies in vitro have shown that an increase in vancomycin concentrations above the minimum inhibitory concentration does not result in more effective killing. The microbiological and clinical efficacy of vancomycin in neonates has only been studied explicitly in a restricted number of patients. There are no definitive data relating serum concentrations to effect in this patient group. Vancomycin-related nephrotoxicity and ototoxicity in neonates is rare, and no clear relation to serum concentrations has been demonstrated. Based on the pharmacokinetic profile of vancomycin in neonates, several administration regimens have been constructed. Recent guidelines have suggested that dosage can be independent of gestational age or postconceptional age in neonates without renal failure. In patients with renal failure, therapy can be adequately tailored by using a regimen based on serum creatinine. The usefulness of routine monitoring of peak serum concentrations is doubtful based on the current literature. Recent research demonstrates a shift towards taking only routine trough serum concentrations in order to optimise efficacy. Patients with renal failure and other special subpopulations, such as patients exposed to ECMO or indomethacin, need to be monitored more closely.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15139793     DOI: 10.2165/00003088-200443070-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  144 in total

1.  Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy.

Authors:  M G Karlowicz; E S Buescher; A E Surka
Journal:  Pediatrics       Date:  2000-12       Impact factor: 7.124

2.  Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin.

Authors:  D C JORDAN; W E INNISS
Journal:  Nature       Date:  1959-12-12       Impact factor: 49.962

3.  In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis.

Authors:  L Herwaldt; L Boyken; M Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

4.  Trough-only monitoring of serum vancomycin concentrations in neonates.

Authors:  F Shackley; P Roberts; P Heath; I Bowler; N J Saunders
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

5.  Why monitor peak vancomycin concentrations?

Authors:  M de Hoog; J W Mouton; J N van den Anker
Journal:  Lancet       Date:  1995-03-11       Impact factor: 79.321

Review 6.  Vancomycin toxicity. What is the evidence for dose dependency?

Authors:  S B Duffull; E J Begg
Journal:  Adverse Drug React Toxicol Rev       Date:  1994

7.  Why monitor peak vancomycin concentrations?

Authors:  N J Saunders
Journal:  Lancet       Date:  1994 Dec 24-31       Impact factor: 79.321

8.  Perioperative complications following the use of vancomycin in children: a report of two cases.

Authors:  C J Best; M Ewart; E Sumner
Journal:  Br J Anaesth       Date:  1989-05       Impact factor: 9.166

9.  Vancomycin pharmacokinetics in small, seriously ill infants.

Authors:  S H Naqvi; W J Keenan; R M Reichley; K P Fortune
Journal:  Am J Dis Child       Date:  1986-02

10.  Bayesian forecasting of serum vancomycin concentrations in neonates and infants.

Authors:  K A Rodvold; C A Gentry; G S Plank; D M Kraus; E Nickel; J R Gross
Journal:  Ther Drug Monit       Date:  1995-06       Impact factor: 3.681

View more
  47 in total

1.  Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.

Authors:  María-Remedios Marqués-Miñana; Anas Saadeddin; José-Esteban Peris
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Predictability of vancomycin pharmacokinetics in neonates.

Authors:  K Allegaert; J N van den Anker
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

3.  Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy.

Authors:  Sazid Hussain; Jinmyoung Joo; Jinyoung Kang; Byungji Kim; Gary B Braun; Zhi-Gang She; Dokyoung Kim; Aman P Mann; Tarmo Mölder; Tambet Teesalu; Santina Carnazza; Salvatore Guglielmino; Michael J Sailor; Erkki Ruoslahti
Journal:  Nat Biomed Eng       Date:  2018-01-22       Impact factor: 25.671

Review 4.  Dosage individualization in children: integration of pharmacometrics in clinical practice.

Authors:  Wei Zhao; Stéphanie Leroux; Evelyne Jacqz-Aigrain
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

5.  Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.

Authors:  Julianne Kim; Sandra A N Walker; Dolores C Iaboni; Scott E Walker; Marion Elligsen; Michael S Dunn; Vanessa G Allen; Andrew Simor
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

6.  Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.

Authors:  Yoke-Lin Lo; Johan G C van Hasselt; Siow-Chin Heng; Chin-Theam Lim; Toong-Chow Lee; Bruce G Charles
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 7.  Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation.

Authors:  Kevin Watt; Jennifer S Li; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

8.  Anti-infective use in children and pregnancy: current deficiencies and future challenges.

Authors:  Amanda Gwee; Noel Cranswick
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

9.  Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation.

Authors:  Sook Hee An; Eun Mi Lee; Jae Yeon Kim; Hye Sun Gwak
Journal:  Eur J Hosp Pharm       Date:  2019-02-20

10.  Optimizing the Use of Antibacterial Agents in the Neonatal Period.

Authors:  Joseph B Cantey
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.